利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.194 秒)

    METHOD AND KIT FOR DISTINGUISHING BETWEEN PROSTATE CARCINOMA AND BENIGN PROSTATIC HYPERPLASIA
    5.
    发明申请
    METHOD AND KIT FOR DISTINGUISHING BETWEEN PROSTATE CARCINOMA AND BENIGN PROSTATIC HYPERPLASIA 有权
    前列腺癌与复发性高血压之间的鉴别方法和试剂盒

    公开(公告)号：US20150260720A1

    公开(公告)日：2015-09-17

    申请号：US14432902

    申请日：2013-10-09

    申请人： HIROSAKI UNIVERSITY ,  SHIZUOKA PREFECTURAL UNIVERSITY CORPORATION

    发明人： Chikara Ohyama ,  Tohru Yoneyama ,  Yuki Tobisawa ,  Shingo Hatakeyama ,  Takashi Suzuki ,  Ilpal Jwa ,  Maho Yamaguchi

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57434 ,  G01N2333/96433 ,  G01N2400/02 ,  G01N2400/12

    摘要： An object of the present invention is to provide a method for distinguishing between prostate carcinoma and benign prostatic hyperplasia with high sensitivity and good reproducibility using a small amount of an analyte sample. The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia according to the present invention as a solution means thereof comprises: bringing an analyte sample containing a prostate-specific antigen (PSA) into contact with a carrier having an anti-free PSA antibody immobilized thereon, thereby binding free PSA to the anti-free PSA antibody immobilized on the carrier; thereafter bringing the carrier in which the free PSA is bound to the immobilized anti-free PSA antibody into contact with a monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an α(2,3) bond, thereby binding the monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an α(2,3) bond to the free PSA bound to the anti-free PSA antibody immobilized on the carrier; measuring the amount of the free PSA having an N-type glycan in which a terminal sialic acid residue is bound to galactose through an α(2,3) bond; comparing the measured amount thus obtained with a preset cutoff value for prostate carcinoma and benign prostatic hyperplasia, thereby determining that when the measured amount is larger than the cutoff value, prostate carcinoma is developed or the probability of developing prostate carcinoma is high, and when the measured amount is smaller than the cutoff value, benign prostatic hyperplasia is developed or the probability of developing benign prostatic hyperplasia is high.

    摘要翻译： 本发明的目的是提供使用少量分析物样品来区分前列腺癌和良性前列腺增生的方法，其具有高灵敏度和良好的再现性。 根据本发明的用于区分前列腺癌和良性前列腺增生的方法作为其溶液方法包括：将含有前列腺特异性抗原（PSA）的分析物样品与其上固定有抗PSA抗体抗体的载体接触 从而将游离PSA结合到固定在载体上的抗自由PSA抗体; 然后将游离PSA与固定化抗体PSA抗体结合的载体与能够特异性识别末端唾液酸残基通过α（2,3）结合到半乳糖的聚糖的单克隆抗体接触， 从而将能够通过α（2,3）键特异性识别末端唾液酸残基与半乳糖结合的聚糖的单克隆抗体结合到与固定在载体上的抗自由PSA抗体结合的游离PSA; 测量其中末端唾液酸残基通过α（2,3）键与半乳糖结合的N-型聚糖的游离PSA的量; 将由此获得的测量量与用于前列腺癌和良性前列腺增生的预设截止值进行比较，从而确定当测量的量大于截止值时，前列腺癌发展或发展为前列腺癌的概率高，并且当 测量量小于临界值，发展良性前列腺增生或发展良性前列腺增生的可能性高。

    Method and kit for distinguishing between prostate carcinoma and benign prostatic hyperplasia
    7.
    发明授权
    Method and kit for distinguishing between prostate carcinoma and benign prostatic hyperplasia 有权

    公开(公告)号：US09933430B2

    公开(公告)日：2018-04-03

    申请号：US14432902

    申请日：2013-10-09

    申请人： HIROSAKI UNIVERSITY ,  Shizuoka Prefectural University Corporation

    发明人： Chikara Ohyama ,  Tohru Yoneyama ,  Yuki Tobisawa ,  Shingo Hatakeyama ,  Takashi Suzuki ,  Ilpal Jwa ,  Maho Yamaguchi

    IPC分类号： G01N33/574 ,  C07K16/18

    CPC分类号： G01N33/57434 ,  G01N2333/96433 ,  G01N2400/02 ,  G01N2400/12

    摘要： The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia comprising: bringing an analyte sample containing a prostate-specific antigen (PSA) into contact with a carrier having an anti-free PSA antibody immobilized thereon, thereby binding free PSA to the anti-free PSA antibody immobilized on the carrier; thereafter bringing the carrier in which the free PSA is bound to the immobilized anti-free PSA antibody into contact with a monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an α(2,3) bond, thereby binding the monoclonal antibody recognizing the glycan to the free PSA bound to the anti-free PSA antibody; measuring the amount of the free PSA having an N-type glycan in which a terminal sialic acid residue is bound to galactose through an α(2,3) bond; comparing the measured amount thus obtained with a preset cutoff value for prostate carcinoma and benign prostatic hyperplasia, thereby determining that when the measured amount is larger than the cutoff value, prostate carcinoma is developed or the probability of developing prostate carcinoma is high, and when the measured amount is smaller than the cutoff value, benign prostatic hyperplasia is developed or the probability of developing benign prostatic hyperplasia is high.